Oxford

OXB (formerly Oxford Biomedica) is a leading global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. Originally spun out of the University of Oxford in 1995, the company has transitioned from a therapeutics developer into a pure-play CDMO focused on viral vector development and manufacturing. OXB's proprietary LentiVector platform is a sector-leading lentiviral vector-based gene delivery system that famously enabled the clinical manufacture of Novartis's breakthrough CAR-T therapy, Kymriah. Operating across facilities in the UK, US, and France, the company provides end-to-end services from early-stage process development to commercial-scale GMP manufacturing for a diverse portfolio of global pharmaceutical and biotechnology clients.